Core Insights - The article discusses the obesity crisis, highlighting that 41.9% of adults in the U.S. are affected, leading to increased cardiovascular diseases and metabolic syndromes [4][5]. - It emphasizes that 90% of weight loss attempts fail due to uncontrolled appetite, which is not merely a matter of willpower but a complex interaction of biological and psychological factors [7][8]. Group 1: Understanding Appetite Control - The article reveals that obesity can trick the brain into craving high-sugar and high-fat foods due to insulin resistance, making it difficult to manage appetite [7][10]. - It identifies three main factors influencing appetite: the brain's reward system, gut microbiota signaling hunger, and emotional stress responses [10][15]. - A new "Desire Decoding System" has been developed to help manage appetite through techniques like biological rhythm adjustment and taste reprogramming [10][15]. Group 2: Effective Weight Loss Strategies - The article presents findings that allowing occasional indulgence in cravings can lead to better weight loss outcomes, with participants losing an average of 7.9% of their body weight [15][18]. - It highlights that strict dieting often leads to stronger cravings and potential binge eating, while moderate indulgence can reduce the desire for unhealthy foods [18][21]. - The research indicates that a "pleasure-based" approach to dieting, which includes a 10% allowance for cravings, can significantly improve weight maintenance success rates [21]. Group 3: Scientific Techniques for Sustainable Weight Loss - The article outlines several techniques for effective appetite management, including prioritizing protein intake, increasing fiber consumption, and practicing mindful eating [19][21]. - It emphasizes the importance of emotional management strategies, such as meditation, to reduce emotional eating triggers [21]. - The findings suggest that sustainable weight loss is achievable through a combination of metabolic reset, behavioral training, and neural adaptation to healthier food choices [19][21].

Core Viewpoint - The article discusses the importance of collaboration between China and the Gates Foundation in global health initiatives, emphasizing China's achievements in health and development, and the need for joint efforts to address global challenges [4][5]. Group 1: China’s Health Achievements - China has established the world's largest disease control and medical service systems, showcasing significant progress in health and wellness [4]. - The country is actively participating in global development cooperation, aiming to enhance health outcomes in developing nations through partnerships [4]. Group 2: Collaboration with the Gates Foundation - The Chinese government expresses a desire to strengthen cooperation with the Gates Foundation, particularly in global health projects that benefit developing countries [4]. - The Gates Foundation acknowledges China's advancements in technology, healthcare, and poverty alleviation, and is eager to enhance its relationship with China to tackle global challenges [5]. Group 3: Global Governance and Stability - The article highlights the importance of stable Sino-American relations for global prosperity, suggesting that both nations should work together to improve global governance and address emerging challenges [4]. - The Gates Foundation is willing to facilitate deeper communication and cooperation between the U.S. and China to achieve practical outcomes in global health and development [5].

Core Viewpoint - The article emphasizes the importance of adhering to the recommended administration guidelines for oral semaglutide to achieve optimal therapeutic effects in weight loss and blood sugar control [2][13]. Administration Guidelines - The recommended way to take oral semaglutide is to consume it with no more than 4 ounces (approximately 120 milliliters) of water before breakfast, ensuring at least a 30-minute interval before eating or drinking anything else [2]. - Taking the medication before any meal or after any meal is less effective due to shorter fasting periods, which can lead to lower plasma concentrations of semaglutide [3]. - If a person only eats lunch and dinner, taking the medication before lunch is acceptable; similarly, if only breakfast and dinner are consumed, taking it before dinner is also permissible [4]. - Taking the medication after meals is not recommended as it significantly diminishes its effectiveness [5]. Timing Considerations - Taking the medication before bedtime is contingent on the fasting duration; if dinner is skipped, it can be taken before sleep, but it is not advisable if dinner is consumed due to insufficient fasting time [7][8]. - The amount of water used to take the medication should not exceed 120 mL, as excessive water can hinder the drug's absorption [9]. - It is crucial to wait at least 30 minutes after taking the medication before consuming breakfast or any other oral medications to avoid interference with absorption [10]. Impact of Non-compliance - Occasional deviations from the recommended administration (e.g., forgetting to take the medication or taking it with too much water) generally have a minimal impact on overall efficacy; however, consistent non-compliance can adversely affect therapeutic outcomes [11][12]. Efficacy Comparison - Oral semaglutide (Rybelsus) and injectable semaglutide (Ozempic) have been shown to have comparable efficacy in clinical trials, with similar reductions in A1C levels and weight loss observed in both [14].

Core Insights - The article discusses the revolutionary impact of GLP-1 receptor agonists, particularly semaglutide, in the treatment of obesity, highlighting its FDA approval and significant weight loss results in clinical trials [6][8] - A new innovative approach combining GLP-1 receptor agonists with NMDA receptor antagonists has shown promising results in animal studies, potentially leading to more effective weight loss solutions [8][11][13] GLP-1 Receptor Agonists - In 2021, the FDA approved semaglutide for long-term weight management, demonstrating an average weight reduction of 15% in obese patients with weekly injections [6] - GLP-1 receptor agonists were initially approved for type 2 diabetes treatment, with their weight loss effects discovered during early trials [8] Innovative Combination Therapy - Researchers from the University of Copenhagen proposed a combination of GLP-1 receptor agonists and NMDA receptor-targeting drugs to enhance weight loss effects [8][11] - The new GLP-1–MK-801 molecule selectively targets NMDA receptors in neurons, avoiding severe side effects seen with non-selective NMDA receptor antagonists [11][13] Experimental Results - In a 14-day study, mice treated with GLP-1–MK-801 showed a remarkable weight loss of 23.2%, significantly outperforming other treatment groups [13] - The combination therapy maintained metabolic rates similar to obese mice, addressing a common challenge in weight loss where metabolism decreases with weight loss [13][14] Safety and Future Research - The safety evaluation of GLP-1–MK-801 indicated no severe adverse reactions in mice, supporting further development of this innovative treatment [14] - Future studies are needed to assess the long-term effects and safety of GLP-1–MK-801, with the potential to become a more powerful treatment option than existing weight loss medications [14] Current GLP-1 Drug Landscape - A list of various GLP-1 drugs in different clinical stages is provided, including FDA-approved medications like Mounjaro (Tirzepatide) and Wegovy (Semaglutide), as well as those in clinical trials [15]

Core Viewpoint - The article discusses the long-term effects of the weight loss drug Semaglutide, highlighting its significant benefits for overweight and obese patients over a treatment period of at least four years, including cardiovascular advantages regardless of weight loss [4][10][11]. Group 1: Semaglutide Overview - Semaglutide, marketed as Wegovy, is an injectable prescription medication approved by the FDA in 2021 for chronic weight management, mimicking the structure of the human hormone GLP-1 to regulate appetite and blood sugar levels [6]. - The drug induces feelings of fullness and slows gastric emptying, reducing the likelihood of overeating, and also helps in blood sugar regulation, being a key component of Ozempic, which is aimed at treating type 2 diabetes [6]. Group 2: Long-term Effects of Semaglutide - A study published in Nature Medicine analyzed the effects of Semaglutide over four years, involving over 17,600 adults who were overweight or obese with a history of cardiovascular disease but without diabetes [8]. - On average, participants using Semaglutide experienced a weight loss of 10% and a reduction in waist circumference of approximately 3 inches, compared to a 1.5% weight loss and 0.5-inch waist reduction in the placebo group [8]. Group 3: Cardiovascular Benefits - A separate study using the same dataset found that Semaglutide treatment provided cardiovascular benefits regardless of participants' initial weight and the amount of weight lost [11]. - The findings suggest that Semaglutide's therapeutic effects extend beyond weight loss, potentially lowering cardiovascular risks through positive impacts on blood sugar, blood pressure, inflammation, and direct effects on the heart and blood vessels [11].

Core Viewpoint - The article discusses the potential of betaine as a "lazy person's exercise" solution, providing metabolic benefits similar to physical exercise for sedentary individuals [5][12]. Group 1: Understanding Betaine - Betaine is a naturally occurring metabolite in the human body that may serve as a true "exercise black technology" [7]. - "Exercise mimetics" are active components that can simulate the effects of exercise through biochemical pathways, tricking the body into thinking it is exercising [8]. Group 2: Scientific Research Findings - A rigorous three-phase human trial was conducted with 13 healthy male participants aged 24-33, utilizing advanced technologies to analyze blood, feces, and physiological indicators [9]. - Key findings include: - After acute exercise, free fatty acids (NEFAs) increased by 2.84 times, and inflammation markers like IL-6 significantly rose [10]. - Long-term exercise led to a notable decrease in triglyceride (TG) levels and a substantial reduction in inflammatory factors (hsCRP, TNF-α) [10]. Group 3: Health Benefits of Betaine - Betaine has multiple health potentials: - Acts as an anti-inflammatory agent, alleviating chronic inflammation related to obesity and aging, thus lowering chronic disease risks [10]. - Enhances antioxidant capacity, protecting liver, kidney, and muscle functions [11]. - Regulates fat metabolism, lowers blood lipids, and improves overall metabolic health [11]. - Can replicate the benefits of exercise at the molecular level, even without physical activity [11]. Group 4: Anti-Aging Research - Recent studies indicate that betaine can rejuvenate aging mice, enhancing grip strength, balance, and endurance, akin to returning to a youthful state [14][16]. - The research highlights four key rejuvenation miracles: - Improved organ function in the liver, kidneys, and muscles, with reduced damage and inflammation [16]. - Inhibition of aging signals and increased expression of antioxidant proteins, leading to reduced oxidative damage [17]. Group 5: Supplementation Guidelines - Natural food sources rich in betaine include beets (114-297 mg per 100g), spinach, wheat germ, quinoa, seafood, and nuts [18]. - Recommended daily intake is 2.5 grams, with a short-term increase to 6 grams under medical supervision [21]. - Emphasis on combining dietary sources with supplements for optimal health benefits [20].

以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 但科学家们还在追问：如果精准"去除"某种特定小分子，而不是简单调整营养比例，身体会发生什么？今年5月，《自然》（Nature）发表的 一项新研究发现，仅仅完全"剔除"半胱氨酸（Cysteine，简称Cys），就能让小鼠在短短7天内减掉30%体重。这个结果极为惊人——去掉一种 小小的氨基酸分子，却像松动了整个机器的关键螺丝，让代谢系统剧烈波动。 半胱氨酸这个名字或许有些陌生，但它其实是人体20种基本氨基酸之一，属于非必需氨基酸——人体可以通过前体物质自行合成，无需完全依 赖食物摄取。除了体内合成外，半胱氨酸在家禽、牛肉、蛋类、谷物等高蛋白食物中也很常见。 与其他氨基酸相比，半胱氨酸有独特的结构——巯基，属于非常"活泼"的侧链，极易在氧化条件下形成二硫键，对蛋白质的折叠和功能至关重 要。同时，这一结构也让半胱氨酸参与合成细胞内重要抗氧化剂——谷胱甘肽（GSH）， ...

整理 | GLP1减重宝典内容团队 然而，兴奋的焦点并不仅仅局限于现有的单重激动剂和双重激动剂。近日，在奥地利维也纳举办的欧洲糖尿病研究学会年会上，来自 德国慕尼黑赫尔姆霍兹糖尿病与肥胖研究所的丹妮拉·利斯基维茨博士等研究人员讨论了一种创新的新型五重激动剂。 该五重激动剂结合了GLP-1R和GIPR激动剂，并与拉尼非普诺（lamifibranor）分子结合，这种分子能激活三种不同的过氧化物酶体增 殖物激活受体（PPARs）——PPAR-α、PPAR-δ和PPAR-γ，这三种受体均在能量调节中发挥重要作用。因此，这种新型化合物总共包 含五种激动剂。 在会议上，利斯基维茨博士分享了关于GLP-1R/GIPR/全PPAR五重激动剂的最新研发进展，并强调其在治疗肥胖相关代谢性疾病中的 潜力。她指出，单分子GLP-1R:GIPR共激动作用已被证明是治疗肥胖和2型糖尿病的有效手段。 此次研究的目标是增强GLP-1R和GIPR共激动作用的代谢益处。利斯基维茨博士的研究小组由提莫·穆勒（Timo Müller）领导，正致力 于设计和评估这种新型五重激动剂，旨在将GLP-1R:GIPR共激动的减重和降血糖效果，与PPAR激动所 ...

整理 | GLP1减重宝典内容团队 随着肥胖和超重问题日益严重，寻找安全有效的治疗药物成为了医学研究的热点。近日，诺和诺德公司启动了一项关于新药NNC0662- 0419的临床研究，旨在评估不同剂量的NNC0662-0419对超重和肥胖患者的疗效和安全性。该药物尚未获得医生处方，但此前已经在 人体上进行了测试，当前正在进行进一步的临床评估。 本研究采取干预性试验设计，所有参与者将接受为期一周一次的治疗，治疗期间会定期监测药物对体重、代谢和健康的影响。研究的 主要目标是观察药物在减重和改善代谢方面的效果，并评估其安全性和耐受性。预计整个研究周期将在2026年底完成。 加入专家库与我们深度讨论 目前，诺和诺德布局了两款三靶点激动剂，包括自研的GLP-1/GIP/Amylin，以及从联邦制药引进的GLP-1/GIP/GCG。 版权声明：所有「GLP1减重宝典」的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则减重宝典将向其追究法律责 任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题，敬请原作者联系我们。合作事宜，请添加微信：andyxu365 「GLP-1俱乐部」覆盖数百位专 ...

整理 | GLP1减重宝典内容团队 近半个世纪以来，亚洲人群的肥胖患病率持续攀升。根据世界卫生组织（WHO）的建议，亚洲人群的肥胖定义标准为BMI≥25 kg/m²，而不是全球普遍采用的≥30 kg/m²。这一差异的原因在于，亚洲人群在相同BMI值下通常具有更高的体脂肪比例，尤其是内脏 脂肪，从而导致更高的代谢和心血管疾病风险。 大量研究已支持司美格鲁肽在减重及改善相关代谢方面的疗效，其中STEP 6和STEP 7试验主要聚焦于BMI≥27 kg/m²的东亚人群。 STEP 11试验则以BMI≥25 kg/m²为基准，进一步评估了司美格鲁肽的疗效。 研究结果表明，在结合生活方式干预的情况下，司美格鲁肽的使用使患者平均减重16.0%（约12.8公斤），其中96%的参与者成功达到 了减重≥5%这一具有临床意义的目标，近一半的患者成功"摆脱肥胖"。此外，患者的"三高"及其他心脏代谢风险因素也显著改善。该 研究结果已发表于《柳叶刀-糖尿病与内分泌学》（The Lancet Diabetes & Endocrinology）。 根据世界卫生组织（WHO）的推荐，亚洲人群的肥胖定义为BMI≥25 kg/m²，因为在较低的 ...